bit.bio, the global leader in cell programming technology, has unveiled its new ioTracker Cells range, with the launch of GFP ioMicroglia as the first product. This innovative tool is designed to accelerate neurodegenerative disease research and drug discovery. It expands upon the company’s ioCells Toolkit, introducing advanced live-cell imaging assay capabilities to enhance its flagship products.
Key Highlights:
- Launch of ioTracker Cells Range: The new range begins with GFP ioMicroglia, a tool developed to aid in the study of complex neurodegenerative diseases and enhance drug discovery.
- Presentation at SLAS 2025: bit.bio will showcase this portfolio of human iPSC-derived cells at the Society for Laboratory Automation and Screening (SLAS) conference from January 25-29, 2025, in San Diego, California. The team will be present at Booth #851, and will also host a panel discussion and several poster sessions to demonstrate the real-world applications of their products.
Statements from Leadership:
- Jonathan Milner, CEO of bit.bio, commented, “With ioTracker Cells, we are empowering researchers to unravel the complexities of the human brain. This new range, starting with GFP ioMicroglia, reflects our mission to deliver transformative tools for biomedical research and drug discovery. Our cells are globally accessible to scientists, accelerating discoveries that can potentially transform our understanding and treatment of neurological diseases.”
- Mark Kotter, Founder of bit.bio, added, “With GFP ioMicroglia, we’re simplifying cell visualization in complex models. Our commitment is to relentlessly innovate cellular tools that allow scientists to study human biology and disease. We look forward to seeing how our customers use these cells to drive novel scientific breakthroughs.”
About GFP ioMicroglia:
- GFP ioMicroglia are engineered to express green fluorescent protein (GFP) in ioMicroglia Male wild type cells.
- These cells exhibit critical functionalities such as phagocytosis and pro-inflammatory cytokine secretion.
- Assay-Ready in 10 days, GFP ioMicroglia are ideal for co-culture with other neural cell types and are designed for live-cell imaging assays, simplifying the assessment of microglia motility and morphology and fluorescent activated cell sorting (FACS) workflows.
Expanded ioCells Portfolio:
bit.bio’s ioCells are human iPSC-derived cells, produced using the company’s proprietary opti-ox™ deterministic cell programming technology. These cells are widely regarded as the best-in-class for:
- Consistency
- Functionality
- Scalability
The ioCells Toolkit now includes 46 products, such as:
- ioWild Type Cells
- ioDisease Model Cells
- ioCRISPR-Ready Cells
- ioTracker Cells
Further Innovation in Neuroscience:
- Farah Patell-Socha, Vice President of Products at bit.bio, stated, “The ioTracker Cells range adds a valuable tool to our neuroscience toolkit. These cells offer a more refined approach to studying neuroinflammation, neurogenesis, and neurodegenerative processes. By enabling precise tracking and isolation in complex in vitro cultures, they help researchers better understand intercellular interactions in disease. Combined with our CRISPR-Ready cells, disease models, and genetically matched controls, these tools provide a comprehensive foundation for advancing neurodegenerative disease research.”
With the launch of GFP ioMicroglia, bit.bio continues to advance its mission to provide transformative tools that aid in the understanding of neurological diseases and accelerate drug discovery. This addition to the ioCells portfolio represents a significant step forward for researchers focused on neuroscience, neuroinflammation, and neurodegenerative disease processes.
